Bio News

U.S.-based Lexeo Therapeutics has agreed to acquire Mantal Therapeutics for an upfront payment of $8.3 million.
Through the acquisition, Lexeo Therapeutics will gain four programs in its Friedreich ataxia (FA) pipeline.
Lexeo Therapeutics plans to submit an investigational new drug (IND) application for a follow-on FA development candidate in 2027.

BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882